Bingkun Wang

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis.

AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis.

Journal: Journal of gastroenterology and hepatology

Published: March 19, 2026

Bile cell-free DNA shows benefit as a potential sample for somatic mutation detection of resectable cholangiocarcinoma.

Bile cell-free DNA shows benefit as a potential sample for somatic mutation detection of resectable cholangiocarcinoma.

Journal: iLIVER

Published: September 15, 2025

Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma.

Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 26, 2024

Epidemiological trends in gastrointestinal cancers and risk factors across U.S. states from 2000 to 2021: a systematic analysis for the global burden of disease study 2021.

Epidemiological trends in gastrointestinal cancers and risk factors across U.S. states from 2000 to 2021: a systematic analysis for the global burden of disease study 2021.

Journal: BMC public health

Published: November 13, 2024

circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation.

circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation.

Journal: Cancer letters

Published: July 11, 2024

FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.

FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.

Journal: Apoptosis : an international journal on programmed cell death

Published: May 15, 2024

A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.

A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: January 16, 2024

CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA.

CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA.

Journal: Cell death & disease

Published: September 03, 2023

Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma.

Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma.

Journal: BMC cancer

Published: July 11, 2023

Identification of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and Responsiveness to Immunotherapy in Hepatocellular Carcinoma.

Identification of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and Responsiveness to Immunotherapy in Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma

Published: November 10, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026